ASTRAZENECA PLC vs PFIZER INC, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where AZN and PFE diverge most: on revenue growth, AZN reads +12.1% and PFE reads +0.2%; on return on assets, AZN reads 9.0% and PFE reads 2.1%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | AZN | PFE |
|---|---|---|
| Price | $159.18 | $28.27 |
| Market cap | $246.7B | $161.1B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | -3.1% |
| P/E | 24.1 | 37.2 |
| P/B | 5.06 | 1.88 |
| P/S | 4.20 | 2.53 |
| EV/EBITDA | 14.3 | 33.9 |
| Revenue growth | +12.1% | +0.2% |
| Gross margin | 81.9% | — |
| Operating margin | 23.4% | — |
| Net margin | 17.4% | 6.8% |
| Return on equity | 21.0% | 5.1% |
| Return on assets | 9.0% | 2.1% |
| Return on invested capital | 14.8% | — |
| FCF yield | 4.8% | 6.8% |
| Dividend yield | — | 6.1% |
| Debt / equity | 0.57 | 0.74 |
| Current ratio | 0.94 | 1.27 |
| Altman Z (solvency) | 3.29 | 1.98 |
| Piotroski F (quality) | 8 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.